323 related articles for article (PubMed ID: 20573993)
1. BNP levels predict outcome in pediatric heart failure patients: post hoc analysis of the Pediatric Carvedilol Trial.
Auerbach SR; Richmond ME; Lamour JM; Blume ED; Addonizio LJ; Shaddy RE; Mahony L; Pahl E; Hsu DT
Circ Heart Fail; 2010 Sep; 3(5):606-11. PubMed ID: 20573993
[TBL] [Abstract][Full Text] [Related]
2. Effect of Carvedilol on Serum Heart-type Fatty Acid-binding Protein, Brain Natriuretic Peptide, and Cardiac Function in Patients With Chronic Heart Failure.
Sun YP; Wei CP; Ma SC; Zhang YF; Qiao LY; Li DH; Shan RB
J Cardiovasc Pharmacol; 2015 May; 65(5):480-4. PubMed ID: 25945865
[TBL] [Abstract][Full Text] [Related]
3. Comparison of plasma B-type natriuretic peptide levels in single ventricle patients with systemic ventricle heart failure versus isolated cavopulmonary failure.
Law YM; Ettedgui J; Beerman L; Maisel A; Tofovic S
Am J Cardiol; 2006 Aug; 98(4):520-4. PubMed ID: 16893709
[TBL] [Abstract][Full Text] [Related]
4. B-type natriuretic peptide predicts adverse cardiovascular events in pediatric outpatients with chronic left ventricular systolic dysfunction.
Price JF; Thomas AK; Grenier M; Eidem BW; O'Brian Smith E; Denfield SW; Towbin JA; Dreyer WJ
Circulation; 2006 Sep; 114(10):1063-9. PubMed ID: 16940194
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of natriuretic Peptide levels to predict mortality in adults with congenital heart disease.
Giannakoulas G; Dimopoulos K; Bolger AP; Tay EL; Inuzuka R; Bedard E; Davos C; Swan L; Gatzoulis MA
Am J Cardiol; 2010 Mar; 105(6):869-73. PubMed ID: 20211335
[TBL] [Abstract][Full Text] [Related]
6. Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction.
Takeda Y; Fukutomi T; Suzuki S; Yamamoto K; Ogata M; Kondo H; Sugiura M; Shigeyama J; Itoh M
Am J Cardiol; 2004 Aug; 94(4):448-53. PubMed ID: 15325927
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction.
Grewal J; McKelvie RS; Persson H; Tait P; Carlsson J; Swedberg K; Ostergren J; Lonn E
Am J Cardiol; 2008 Sep; 102(6):733-7. PubMed ID: 18773998
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of serum brain natriuretic peptide to predict adverse events in patients with the Eisenmenger syndrome.
Reardon LC; Williams RJ; Houser LS; Miner PD; Child JS; Aboulhosn JA
Am J Cardiol; 2012 Nov; 110(10):1523-6. PubMed ID: 22863176
[TBL] [Abstract][Full Text] [Related]
9. B-type natriuretic peptide levels in obese patients with advanced heart failure.
Horwich TB; Hamilton MA; Fonarow GC
J Am Coll Cardiol; 2006 Jan; 47(1):85-90. PubMed ID: 16386669
[TBL] [Abstract][Full Text] [Related]
10. [Prognostic value of BNP and cardiopulmonary exercise testing in patients with systolic heart failure on beta-blocker therapy].
Pascual-Figal DA; Peñafiel P; Nicolas F; de la Morena G; Ansaldo P; Redondo B; Sánchez Mas J; Valdés M
Rev Esp Cardiol; 2008 Mar; 61(3):260-8. PubMed ID: 18361899
[TBL] [Abstract][Full Text] [Related]
11. Prognostic utility of B-type natriuretic peptide assessment in stable low-risk outpatients with nonischemic cardiomyopathy after decompensated heart failure.
Nishii M; Inomata T; Takehana H; Naruke T; Yanagisawa T; Moriguchi M; Takeda S; Izumi T
J Am Coll Cardiol; 2008 Jun; 51(24):2329-35. PubMed ID: 18549918
[TBL] [Abstract][Full Text] [Related]
12. Baseline and serial neurohormones in patients with congestive heart failure treated with and without bucindolol: results of the neurohumoral substudy of the Beta-Blocker Evaluation of Survival Study (BEST).
Frantz RP; Lowes BD; Grayburn PA; White M; Krause-Steinrauf H; Krishnan V; Uyeda L; Burnett JC;
J Card Fail; 2007 Aug; 13(6):437-44. PubMed ID: 17675057
[TBL] [Abstract][Full Text] [Related]
13. Low prevalence of B-type natriuretic peptide levels < 100 pg/mL in patients with heart failure at hospital discharge.
Hogenhuis J; Voors AA; Jaarsma T; Hillege HL; Hoes AW; van Veldhuisen DJ
Am Heart J; 2006 May; 151(5):1012.e1-5. PubMed ID: 16644323
[TBL] [Abstract][Full Text] [Related]
14. Concentration of BNP, endothelin 1, pro-inflammatory cytokines (TNF-alpha, IL-6) and exercise capacity in patients with heart failure treated with carvedilol.
Nessler J; Nessler B; Kitliński M; Gackowski A; Piwowarska W; Stepniewski M
Kardiol Pol; 2008 Feb; 66(2):144-51; discussion 152-3. PubMed ID: 18344152
[TBL] [Abstract][Full Text] [Related]
15. Effect of beta-blockade and ACE inhibition on B-type natriuretic peptides in stable patients with systolic heart failure.
Rosenberg J; Gustafsson F; Remme WJ; Riegger GA; Hildebrandt PR
Cardiovasc Drugs Ther; 2008 Aug; 22(4):305-11. PubMed ID: 18309461
[TBL] [Abstract][Full Text] [Related]
16. Brain natriuretic peptide and cardiac resynchronization therapy in patients with mildly symptomatic heart failure.
Brenyo A; Barsheshet A; Rao M; Huang DT; Zareba W; McNitt S; Hall WJ; Peterson DR; Solomon SD; Moss AJ; Goldenberg I
Circ Heart Fail; 2013 Sep; 6(5):998-1004. PubMed ID: 23801020
[TBL] [Abstract][Full Text] [Related]
17. Letter by Lowenthal et al regarding article, "BNP levels predict outcome in pediatric heart failure patients: post hoc analysis of the Pediatric Carvedilol Trial".
Lowenthal A; Shah A; Bernstein HS
Circ Heart Fail; 2010 Nov; 3(6):e32; author reply e33. PubMed ID: 21081737
[No Abstract] [Full Text] [Related]
18. Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure.
Frantz RP; Olson LJ; Grill D; Moualla SK; Nelson SM; Nobrega TP; Hanna RD; Backes RJ; Mookadam F; Heublein D; Bailey KR; Burnett JC
Am Heart J; 2005 Mar; 149(3):541-7. PubMed ID: 15864245
[TBL] [Abstract][Full Text] [Related]
19. B-type natriuretic Peptide-guided treatment for predicting outcome in patients hospitalized in sub-intensive care unit with acute heart failure.
Valle R; Aspromonte N; Giovinazzo P; Carbonieri E; Chiatto M; di Tano G; Feola M; Milli M; Fontebasso A; Barro S; Bardellotto S; Milani L
J Card Fail; 2008 Apr; 14(3):219-24. PubMed ID: 18381185
[TBL] [Abstract][Full Text] [Related]
20. Carvedilol reduces elevated B-type natriuretic peptide in dialyzed patients without heart failure: cardioprotective effect of the beta-blocker.
Kojima M; Sato K; Kimura G; Ueda R; Dohi Y
J Cardiovasc Pharmacol; 2007 Apr; 49(4):191-6. PubMed ID: 17438403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
